Thynk Capital

Operator of a futures/derivatives exchange designed to focus on healthcare. The company's platform creates a transparent, two-sided market for the pricing of healthcare assets, and provides hedging opportunities for payers and providers, and other healthcare market participants, enabling healthcare stakeholders to compete for services and cushioning price shocks in the marketplace, leading to lower prices and premiums.

IVIVA Medical, Inc. develops bio-artificial platforms and systems to provide therapies. It develops alternative end-state renal disease therapies that alleviate donor organ demand for patients; disease and pathology modeling; and bioreactor systems. The company was incorporated in 2013 and is based in Beverly, Massachusetts.

Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”). Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.

Repair Biotechnologies, Inc. is a biotechnology company based in Syracuse, New York, established in 2018. The company focuses on developing innovative gene and protein therapies aimed at reversing age-related conditions such as immunosenescence and atherosclerosis. It addresses critical issues like thymic atrophy and the associated decline in immune function, which are prevalent in aging populations. By targeting the root causes of age-related diseases, Repair Biotechnologies aims to enhance the health span of individuals and improve overall well-being. The company employs a cholesterol-degrading platform to tackle localized accumulations of excess cholesterol, promoting safe and effective treatments for related medical conditions.

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.

Repair Biotechnologies, Inc. is a biotechnology company based in Syracuse, New York, established in 2018. The company focuses on developing innovative gene and protein therapies aimed at reversing age-related conditions such as immunosenescence and atherosclerosis. It addresses critical issues like thymic atrophy and the associated decline in immune function, which are prevalent in aging populations. By targeting the root causes of age-related diseases, Repair Biotechnologies aims to enhance the health span of individuals and improve overall well-being. The company employs a cholesterol-degrading platform to tackle localized accumulations of excess cholesterol, promoting safe and effective treatments for related medical conditions.

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.

KitoTech Medical is a medical device company based in Seattle, Washington, focused on developing and commercializing innovative products for wound closure and care. The company's flagship product, microMend, features a unique design that incorporates tiny Microstaples on an adhesive backing, resembling a butterfly bandage. This product is painless to apply and offers the holding strength of traditional sutures, making it suitable for closing surgical incisions and lacerations. Clinical studies indicate that microMend outperforms sutures in various clinical outcomes, including cosmetic results, and can be applied more quickly by a range of medical personnel, resulting in significant cost savings. microMend is marketed across numerous surgical specialties, as well as in dermatology and emergency medicine, with additional commercialization efforts targeting military applications. The potential market for microMend is substantial, estimated at over $600 million in the U.S. and around $2 billion globally. KitoTech Medical was founded in 2011.

Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Elevian, Inc. is a biotechnology company based in Menlo Park, California, founded in 2017. The company is focused on developing therapeutics aimed at restoring regenerative capacity to prevent and treat age-related diseases. Elevian's research centers on the Growth Differentiation Factor 11 (GDF11) protein and other circulating factors that stimulate regeneration in various tissues, including the brain, heart, pancreas, and muscles. The company's therapeutic candidates target the root causes of aging and aim to address conditions such as stroke recovery, Alzheimer's disease, coronary artery disease, and Type 2 diabetes. By identifying and regulating blood factors that influence aging, Elevian seeks to enable effective treatments that enhance the body’s natural repair and regeneration mechanisms.

Theragene Pharmaceuticals combines innovative science and efficiency to develop life-saving therapies for many debilitating diseases. As a biopharmaceutical company operating in both the US and Asia, it delivers unique product development models, utilizing the strengths of each region, while delivering safe, effective treatments. Its mission is to provide cutting-edge science, through resourceful product models, that significantly advance each product from the preclinical stage to finished product. From advancements in oncology to novel drug formulations, they are developing tomorrow's medicine.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

Klotho Therapeutics is a biotechnology company based in San Diego, California, focused on developing modified versions of the Klotho protein to address aging-related diseases. Founded in 2016, the company aims to prevent and slow the progression of chronic kidney diseases, acute kidney injuries, diabetes, Alzheimer's, osteoporosis, cancer, and hypertension. Research indicates that Klotho plays a significant role in extending lifespan and promoting health, with studies showing that Klotho-deficient animals exhibit accelerated aging and shorter lifespans, while those with increased Klotho expression tend to live significantly longer. The company’s primary focus is on kidney failure, a critical health issue impacting millions in the U.S., with no effective long-term therapies currently available. Klotho Therapeutics has secured patents for its modified Klotho proteins, highlighting their potential to redefine treatment for aging-related conditions and improve patient outcomes.

Fisker, Inc. is a designer and manufacturer of electric vehicles and mobility solutions, headquartered in Manhattan Beach, California. The company aims to revolutionize the automotive industry by creating eco-friendly vehicles that evoke emotional responses from consumers. Fisker's commitment to sustainability is reflected in its focus on producing electric vehicles that align with modern environmental standards. The company has a notable history, having previously produced the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which garnered attention during its debut at the 2008 North American International Auto Show. Although production of the Karma was halted in 2012, Fisker has since shifted its focus towards developing innovative electric vehicles that meet the growing demand for sustainable transportation solutions.

Curtana Pharmaceuticals, based in Austin, Texas, specializes in developing targeted therapies for aggressive brain cancers, including glioblastoma and pediatric medulloblastoma. Founded in 2013, the company focuses on creating novel molecular therapies, notably CT-179, which aims to prolong survival in relevant animal models. The development program is rooted in the research of Dr. Santosh Kesari, a leading figure in neuro-oncology. Curtana's approach integrates Olig2 inhibitors with conventional treatment options to enhance therapeutic outcomes. The company has garnered significant support, including a $7.6 million grant from the Cancer Prevention and Research Institute of Texas, which facilitated its relocation from San Diego to Austin. With a seasoned leadership team experienced in oncology and central nervous system disorders, Curtana is committed to pioneering advancements in brain cancer treatment.

WinSanTor Inc. is a clinical-stage biotechnology company based in San Diego, California, established in 2011. The company specializes in the discovery and development of treatments for various forms of peripheral neuropathies, such as diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and HIV-induced neuropathy. WinSanTor is engaged in identifying and developing therapeutic compounds, including WST57, aimed at providing neuroprotection and promoting neuroregeneration in degenerating neurons.

Lubris BioPharma, LLC, a biopharmaceutical company, produces and commercializes lubricin, a recombinant version of the human protein. It offers its product for the treatment of dry eye, osteoarthritis, and other age and inflammation-related conditions. The company was founded in 2009 and is based in Framingham, Massachusetts.